A Phase I Clinical Trial of SyB L-0501 in Combination With Rituximab to Patients With Aggressive B-cell Non-Hodgkin's Lymphoma

Inclusion Criteria: Aggressive B-cell non-Hodgkin's lymphoma patients with prior therapy who satisfy the conditions listed below. No restrictions regarding gender. * Patients with the following histologically confirmed CD20(+) B-cell non-Hodgkin's lymphoma: 1. Diffuse large B-cell lymphoma 2. Mantle cell lymphoma 3. Transformed lymphoma 4. Follicular lymphoma (Grade 3) * Fail to CR in prior chemotherapy, or relapse following CR or recurrence following PR. * Patients who are judged to carry no effect from the prior therapy (cancer chemotherapy, antibody therapy and radiation/ radiotherapy. * Patients aged from 20 to 75 years at the time informed consent is obtained * Patients with adequately maintained organ functions (e.g., bone marrow, heart, lung, liver, and kidney functions) * Patients who can be hospitalized during the first cycle * Patients capable of personally giving voluntary informed consent in writing to participate in the study Exclusion Criteria: Patients who meet any of the following criteria will be excluded. * Patients with serious complications (hepatic or renal failure) * Patients with complications or medical history of serious cardiac disease (e.g., myocardial infarction, ischemic heart disease) * Patients with serious gastrointestinal symptoms (e.g., severe nausea, vomiting, or diarrhea) * Patients positive for HBs antigen, HCV antibody, or HIV antibody * Patients who received other investigational drug or unapproved medication within 3 months before registration in this study * Patients who had history of hematopoietic stem cell transplantation or radioimmunotherapy * Patients who are pregnant, of childbearing potential, or lactating * Patients, whether male or female, who do not agree to contraception * Patients otherwise judged by investigator or sub investigator to be unsuitable